14-Gene Assay for Early NSCLC Treatment
- A new study presented at the 2025 American Society of Clinical Oncology Annual Meeting suggests a 14-gene classifier can effectively predict wich patients with early-stage non-small cell lung...
- The study focused on disease-free survival (DFS) as the primary endpoint.
- According to Spigel, the 14-gene classifier has been in progress for nearly a decade, with initial validation studies indicating its potential for accurately identifying high-risk patients.
A groundbreaking 14-gene assay is revolutionizing early-stage NSCLC treatment. This innovative gene test accurately predicts which patients with non-small cell lung cancer benefit most from chemotherapy after surgery,leading to a 78% reduction in cancer recurrence or death for high-risk patients. dr. David Spigel’s research, unveiled at the 2025 ASCO Annual Meeting, confirms the assay’s effectiveness as a pivotal tool for personalized medicine. The test, commercially available and delivering results in about ten days, empowers informed decisions on adjuvant chemotherapy, offering clarity when uncertainty reigns. This advancement, covered by most insurance plans, marks a important leap forward. Discover how News Directory 3 is reporting on these pivotal findings.What other therapies will be explored?
Gene Test Predicts chemo Need in Early Lung Cancer
Updated June 03,2025
A new study presented at the 2025 American Society of Clinical Oncology Annual Meeting suggests a 14-gene classifier can effectively predict wich patients with early-stage non-small cell lung cancer (NSCLC) require chemotherapy after surgery. The research, led by Dr. David spigel at Sarah Cannon Research Institute, found that high-risk patients identified by the test experienced a notable reduction in cancer recurrence or death when receiving chemotherapy.
The study focused on disease-free survival (DFS) as the primary endpoint. Patients classified as intermediate- or high-risk who received chemotherapy showed superior DFS compared to those who did not. Specifically, chemotherapy led to a 78% reduction in the risk of cancer returning or death within this high-risk group.
According to Spigel, the 14-gene classifier has been in progress for nearly a decade, with initial validation studies indicating its potential for accurately identifying high-risk patients. This prospective, randomized trial further confirmed its effectiveness in guiding treatment decisions for early-stage NSCLC, offering a valuable tool for personalized medicine in lung cancer treatment.
The molecular assay is now commercially available,allowing health care professionals to order the test and receive results within approximately 10 days. spigel emphasized that the test is most useful in cases where the role of chemotherapy is uncertain, helping patients, families, and doctors make informed decisions about adjuvant chemotherapy.
“The goal of this study was to use a gene classifier to help predict which patients would be at the highest risk for recurrence and offer them a chance for chemotherapy where they may not otherwise receive that,” Spigel said.
While the test is covered by most insurance plans, Spigel anticipates some challenges in widespread implementation, mainly related to awareness and understanding among health care professionals. He likened it to similar tests used in colon and prostate cancer, emphasizing the importance of educating both doctors and patients about its benefits in informing treatment choices.
What’s next
The availability of this 14-gene classifier promises to refine treatment strategies for early-stage NSCLC, ensuring that chemotherapy is administered to those patients who will genuinely benefit, while sparing others from unnecessary side effects. Further studies may explore its request in combination with newer therapies.